END 7-OH Act
- Sponsor
- Rep. Bilirakis, Gus M. [R-FL-12]
- Committees
- Judiciary Committee (primary)
- Last action
- Mar 19, 2026
Bottom line
This bill criminalizes synthetic versions of a compound found in kratom, aiming to prevent the proliferation of potentially more potent and dangerous synthetic drugs while preserving the legal status of natural kratom.
What it actually does
This bill amends the Controlled Substances Act to classify synthetic 7-hydroxymitragynine as a Schedule I controlled substance. This action makes the manufacture, distribution, and possession of synthetic versions of this compound illegal under federal law. Crucially, the bill explicitly exempts 7-hydroxymitragynine that is naturally contained in the plant Mitragyna speciosa Korth, commonly known as kratom.
Proponents argue
Supporters argue that this bill is a proactive and necessary measure to prevent the emergence of a new class of dangerous synthetic drugs. They contend that synthetic 7-hydroxymitragynine could be significantly more potent and addictive than its natural counterpart, posing a serious public health risk similar to other synthetic opioids. By specifically scheduling only the synthetic form, proponents aim to protect public safety without impacting the legal status of natural kratom, which some users claim has therapeutic benefits.
Opponents contend
Opponents might argue that scheduling any form of 7-hydroxymitragynine, even synthetic, could set a precedent that eventually leads to broader restrictions on natural kratom, which many individuals use for pain management or to mitigate opioid withdrawal symptoms. Some may also contend that focusing solely on synthetic versions might be difficult to enforce or that the scientific understanding of the specific dangers of synthetic 7-hydroxymitragynine is still developing, making a Schedule I classification premature.
The bill is very short and clearly written, allowing for a quick and thorough understanding of its provisions by any informed reader.
Section 2
Scheduling of Synthetic 7-Hydroxymitragynine
This section amends Schedule I of the Controlled Substances Act (CSA) to include 7-hydroxymitragynine, specifically its synthetic equivalents. Under federal law, Schedule I substances are deemed to have a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. Importantly, the bill explicitly states that 7-hydroxymitragynine naturally contained in the kratom plant (Mitragyna speciosa Korth) is not included in this scheduling, thereby maintaining the current legal status of natural kratom.
Supporters argue
Supporters argue that this provision is crucial for public safety, preventing the illicit manufacture and distribution of potentially dangerous synthetic substances that could mimic or exceed the effects of opioids. They emphasize the clear distinction between synthetic and natural forms, ensuring that the bill targets only novel, potentially more potent synthetic variants, thereby protecting the public without affecting natural kratom.
Critics contend
Critics might express concern that even with the explicit exemption, scheduling a component related to kratom could be seen as a step towards broader regulation or prohibition of natural kratom in the future, impacting individuals who use it for various purposes. Some may also argue that a Schedule I classification is too restrictive for a substance whose full pharmacological profile, especially in synthetic forms, might still be under investigation.
Tradeoffs
The bill attempts to balance the desire to prevent the proliferation of dangerous synthetic drugs with concerns about potentially over-regulating substances related to natural products like kratom. It navigates this tension by specifically targeting synthetic versions, acknowledging the ongoing debate around kratom's legal status and perceived benefits while addressing perceived risks from novel synthetic variants.